200 related articles for article (PubMed ID: 12296390)
1. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
Shryock TR; Staples JM; DeRosa DC
J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
[TBL] [Abstract][Full Text] [Related]
2. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella spp. associated with bovine respiratory disease.
Shryock TR; White DW; Staples JM; Werner CS
J Vet Diagn Invest; 1996 Jul; 8(3):337-44. PubMed ID: 8844577
[TBL] [Abstract][Full Text] [Related]
3. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
[No Abstract] [Full Text] [Related]
4. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
Dayao D; Gibson JS; Blackall PJ; Turni C
Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
[TBL] [Abstract][Full Text] [Related]
6. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
7. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Moore GM; Basson RP; Tonkinson LV
Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs.
Raemdonck DL; Tanner AC; Tolling ST; Michener SL
Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of porcine respiratory pathogens to tilmicosin.
DeRosa DC; Veenhuizen MF; Bade DJ; Shryock TR
J Vet Diagn Invest; 2000 Nov; 12(6):541-6. PubMed ID: 11108454
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens.
Bousquet E; Morvan H; Aitken I; Morgan JH
Vet Rec; 1997 Jul; 141(2):37-40. PubMed ID: 9253829
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tilmicosin phosphate (Pulmotil premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs.
Hoflack G; Maes D; Mateusen B; Verdonck M; de Kruif A
J Vet Med B Infect Dis Vet Public Health; 2001 Nov; 48(9):655-64. PubMed ID: 11765801
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of enteric-coated tilmicosin granules in pigs artificially infected with Actinobacillus pleuropneumoniae serotype 2.
Dong Z; Zhou XZ; Sun JC; Meng XB; Li HS; Cheng FS; Wei XJ; Li B; Wang WW; Zhang JY
Vet Med Sci; 2020 Feb; 6(1):105-113. PubMed ID: 31589010
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the efficacy of tilmicosin phosphate to eliminate Actinobacillus pleuropneumoniae from carrier pigs.
Fittipaldi N; Klopfenstein C; Gottschalk M; Broes A; Paradis MA; Dick CP
Can J Vet Res; 2005 Apr; 69(2):146-50. PubMed ID: 15971680
[TBL] [Abstract][Full Text] [Related]
15. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey L; Lees P
BMC Vet Res; 2017 Jun; 13(1):192. PubMed ID: 28645327
[TBL] [Abstract][Full Text] [Related]
16. In vitro microbiological characterization of novel macrolide CP-163,505 for animal health specific use.
Norcia LJ; Seibel SB; Kamicker BJ; Lemay MA; Lilley SC; Hecker SJ; Bergeron JM; Retsema JA; Hayashi SF
J Antibiot (Tokyo); 1998 Feb; 51(2):136-44. PubMed ID: 9544934
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial resistance of Actinobacillus pleuropneumoniae isolated from swine.
Vanni M; Merenda M; Barigazzi G; Garbarino C; Luppi A; Tognetti R; Intorre L
Vet Microbiol; 2012 Apr; 156(1-2):172-7. PubMed ID: 22104584
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study.
de Jong A; Thomas V; Simjee S; Moyaert H; El Garch F; Maher K; Morrissey I; Butty P; Klein U; Marion H; Rigaut D; Vallé M
Vet Microbiol; 2014 Aug; 172(1-2):202-15. PubMed ID: 24837878
[TBL] [Abstract][Full Text] [Related]
19. Whole Genome Sequence Analysis of Pig Respiratory Bacterial Pathogens with Elevated Minimum Inhibitory Concentrations for Macrolides.
Dayao DA; Seddon JM; Gibson JS; Blackall PJ; Turni C
Microb Drug Resist; 2016 Oct; 22(7):531-537. PubMed ID: 26981707
[TBL] [Abstract][Full Text] [Related]
20. Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics.
Xiong J; Zhu Q; Zhao Y; Yang S; Cao J; Qiu Y
J Vet Pharmacol Ther; 2019 May; 42(3):336-345. PubMed ID: 30801755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
